Abstract
[Summary] Treatment of type 2 diabetes which is characterized by the progressive β-cell dysfunction currently faces various challenges.A new generation of drug need to protect β-cell function in early stage of the disease.Liraglutide is a glucagon-like peptide 1 analogue and provides a new therapeutic option due to its unique clinical efficacy.Early and long-term usage of liraglutide improves glycemic control,reduces body weight and systolic blood pressure,as well as protects β-cell function for the patients with diabetes. Key words: Liraglutide; Diabetes mellitus, type 2; β-cell ; Comprehensive management
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
